Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis

被引：0

作者：

Podzamczer, D. ^{[1
]}

Imaz, A. ^{[2
]}

Lopez-Lirola, A. ^{[3
]}

Knobel, H. ^{[4
]}

Masia, M. ^{[5
]}

Fanciulli, C. ^{[6
]}

Hernadez, C. ^{[7
]}

Lagarde, M. ^{[8
]}

Gutierrez, A. ^{[9
]}

Curran, A. ^{[10
]}

Morano, L. ^{[11
]}

Montero-Alonso, M. ^{[12
]}

Troya, J. ^{[13
]}

Rigo, R.

Casadella, M. ^{[14
]}

Navarro-Alcaraz, A. ^{[14
]}

Ardila, F.

Parera, M. ^{[14
]}

Bernal, E. ^{[15
]}

Echeverria, P. ^{[16
]}

Estrada, V. ^{[17
]}

Hidalgo-Tenorio, C. ^{[18
]}

Macias, J. ^{[19
]}

Priet, P. ^{[20
]}

Portilla, J. ^{[21
]}

Valencia, E. ^{[22
]}

Vivancos, M. J. ^{[23
]}

Rivero, A.

机构：

[1] Fight Infect Fdn, Badalona, Spain

[2] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Univ Gen Elche, Elche, Spain

[5] Hosp Gen Univ Gregorio Maran, Inst Invest Sanitaria Gregorio Maran IiSGM, Ctr Invest Biomed Red Enfermedades Infecc, Madrid, Spain

[6] Hosp Principe Asturias, Alcala De Henares, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Univ Princesa, Madrid, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Hosp Univ Alvaro Cunqueiro, Vigo, Spain

[11] Hosp Univ Politecn La Fe, Valencia, Spain

[12] Hosp Univ Infanta Leonor, Madrid, Spain

[13] IrsiCaixa Inst Recerca SIDA, Badalona, Spain

[14] Hosp Univ Reina Sofia, Murcia, Spain

[15] Hosp Badalona Germans Trias & Pujol, Fight Infect Fdn, Badalona, Spain

[16] Hosp Clin San Carlos, Madrid, Spain

[17] Hosp Univ Virgen de Ias Nieves, Granada, Spain

[18] Univ Seville, IBiS,Hosp Univ Virgen de Valme, Inst Biomed Sevilla,Unidad Enfermedades Infecc &, CIBERINFEC,Dept Med,CSIC, Seville, Spain

[19] Hosp Univ Santa Creu & St Pau, Barcelona, Spain

[20] Hosp Gen Univ Alicante, Alicante, Spain

[21] Hosp Univ La Paz, Madrid, Spain

[22] Hosp Univ Ramon y Cajal, Madrid, Spain

[23] Univ Cordoba UCO, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, ISCIII CIBER Enfermedades Infecc Inst Salud Carlo, Cordoba, Spain

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

EACS2023:

引用

页码：310 / 311

页数：2

共 50 条

[1] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Podzamczer, Daniel
Imaz, Arkaitz
Lopez-Lirola, Ana
Knobel, Hernando
Masia, Mar
Fanciulli, Chiara
Hernandez, Cristina
Lagarde, Maria
Gutierrez, Angela
Curran, Adria
Morano, Luis
Montero-Alonso, Marta
Troya, Jesus
Rigo, Raul
Casadella, Maria
Navarro-Alcaraz, Antonio
Ardila, Fernando
Parera, Mariona
Bernal, Enrique
Echeverria, Patricia
Estrada, Vicente
Hidalgo-Tenorio, Carmen
Macias, Juan
Prieto, Paula
Portilla, Joaquin
Valencia, Eulalia
Vivancos, Maria Jesus
Rivero, Antonio
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701
[2] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat (DRV/c) in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Podzamczer, D.
Imaz, A.
Lopez Lirola, A.
Knobel, H.
Masia, M.
Berenguer, J.
Hernandez, C.
Lagarde, M.
Gutierrez, A.
Curran, A.
Morano, L.
Montero-Alonso, M.
Troya, J.
Rigo, R.
Casadella, M.
Navarro-Alcaraz, A.
Rivero Roman, A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 81 - 82
[3] Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline
Mounzer, K.
Slim, J.
Ramgopal, M.
Hedgcock, M.
Bloch, M.
Santana, J.
Mendes, I.
Zhang, X.
Sklar, P.
Montezuma-Rusca, J. M.
Segal-Maurer, S.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 16 - 16
[4] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Orkin, Chloe
Molina, Jean-Michel
Negredo, Eugenia
Arribas, Jose R.
Gathe, Joseph
Eron, Joseph J.
Van Landuyt, Erika
Lathouwers, Erkki
Hufkens, Veerle
Petrovic, Romana
Vanveggel, Simon
Opsomer, Magda
LANCET HIV, 2018, 5 (01): : E23 - E34
[5] Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
Rolle, Charlotte-Paige
Castano, Jamie
Nguyen, Vu
Hinestrosa, Federico
Dejesus, Edwin
OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
[6] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis
Dunn, Keith
Bushen, Jennifer
Luo, Donghan
Cai, Jiyun
Simonson, Richard Bruce
Anderson, David
HIV MEDICINE, 2023, 24 (03) : 279 - 289
[7] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Molina, J-M
Gallant, J.
Orkin, C.
Negredo, E.
Bhatti, L.
Gathe, J.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Vanveggel, S.
Opsomer, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
[8] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Henry, Keith
Santana-Bagur, Jorge
Stein, David K.
Bellos, Nicholaos
Scarsella, Anthony
Yan, Mingjin
Abram, Michael E.
Cheng, Andrew
Rhee, Martin S.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 226 - 231
[9] A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
Huhn, Gregory D.
Tebas, Pablo
Gallant, Joel
Wilkin, Timothy
Cheng, Andrew
Yan, Mingjin
Zhong, Lijie
Callebaut, Christian
Custodio, Joseph M.
Fordyce, Marshall W.
Das, Moupali
McCallister, Scott
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 193 - 200
[10] Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
Avihingsanon, Anchalee
Chetchotisakd, Ploenchan
Kiertiburanakul, Sasisopin
Ratanasuwan, Winai
Siripassorn, Krittaecho
Supparatpinyo, Khuanchai
Martin, Hal
Wang, Hui
Wong, TinHung
Wang, Hsiu Yin
HIV MEDICINE, 2023, 24 (03) : 290 - 300

← 1 2 3 4 5 →